Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > BioNanomatrix Appoints Gary Zweiger, Ph.D., as Vice President of Business Development

Abstract:
--Appointment Expands Leadership Team and Strengthens Commercial Focus--

BioNanomatrix Appoints Gary Zweiger, Ph.D., as Vice President of Business Development

Philadelphia, PA | Posted on December 2nd, 2008

BioNanomatrix, Inc., a developer of breakthrough nanoscale platforms for molecular diagnostics, personalized medicine and biomedical research, today announced the appointment of Gary Zweiger, Ph.D., as vice president of business development. Dr. Zweiger has over a decade of strategic business development experience with leading biotechnology and genomics companies. He will focus on expanding BioNanomatrix's commercial and research partnerships for its breakthrough nanoscale whole genome technology platform in multiple markets, including research, diagnostics and personalized medicine.

"Gary's background and experience are close to ideal for our newly created senior business development position, and we are very pleased to have him on board," said Dr. Michael Boyce-Jacino, chief executive officer of BioNanomatrix. "Gary's scientific expertise is directly relevant to our end-user markets and his extensive business development and alliance management experience should be invaluable as we expand our network of collaborations and commercial partnerships."

BioNanomatrix is applying its expertise in nanochips, nanodevices and nanosystems to develop its platform technology providing fast, comprehensive and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Among its current development efforts is a federally funded project in partnership with Complete Genomics Inc. for very low-cost sequencing of the human genome.

"This is an exciting time to join BioNanomatrix as the company is advancing a potentially transformative single-molecule, whole genome sorting and imaging technology that will enable scientists to analyze clinically relevant DNA sequence variation, copy number and positional information, and to do so much faster, more cost-effectively and with far better resolution than existing methods," said Dr. Zweiger. "There are many possible applications for our technology, and I look forward to working with the BioNanomatrix team to expand the company's growing list of partnerships and help establish new opportunities for growth."

Prior to joining BioNanomatrix, Dr. Zweiger was senior director of business development at Affymetrix, where he managed collaborations, developed new business opportunities and secured revenue-generating research partnerships. Previously, he was director of business development for Applied Biosystems' Cell and Molecular Biology division, where he managed collaborations and business development activities for the company's PCR, DNA sequencing, RNA interference and cell biology businesses. Prior to Applied Biosystems, Dr. Zweiger was at Agilent Technologies, where he held positions of increasing responsibility, directing efforts to identify, assess and secure new business opportunities. Earlier in his career, Dr. Zweiger served as a strategic advisor and consultant to biotechnology and genomics companies and to the financial community. He has published a general audience book on sequencing the human genome, authored numerous scientific publications and holds seven patents. Dr. Zweiger received a Ph.D. in genetics and a B.S. in biological sciences from Stanford University and completed a post-doctoral fellowship in molecular oncology at Genentech Inc.

####

About BioNanomatrix, Inc.
BioNanomatrix isdeveloping breakthrough nanoscale whole genome imaging and analytic platforms for applications in genetic diagnostics, personalized medicine and biomedical research. The company is applying its expertise in nanochips, nanodevices and nanosystems to develop its patented platform technology to provide fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Its current development efforts include a federally funded project to sequence the human genome at a cost of $100. BioNanomatrix's technologies are licensed exclusively from Princeton University. Founded in 2003, the company is headquartered in Philadelphia, Pennsylvania.

For more information, please click here

Contacts:
Barbara Lindheim
GendeLLindheim BioCom Partners
212 918-4650

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Automating DNA origami opens door to many new uses: Like 3-D printing did for larger objects, method makes it easy to build nanoparticles out of DNA May 30th, 2016

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

Doubling down on Schrödinger's cat May 27th, 2016

Nanomedicine

Automating DNA origami opens door to many new uses: Like 3-D printing did for larger objects, method makes it easy to build nanoparticles out of DNA May 30th, 2016

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

Supercrystals with new architecture can enhance drug synthesis May 24th, 2016

Announcements

Automating DNA origami opens door to many new uses: Like 3-D printing did for larger objects, method makes it easy to build nanoparticles out of DNA May 30th, 2016

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

Doubling down on Schrödinger's cat May 27th, 2016

Appointments/Promotions/New hires/Resignations/Deaths

Park Systems Global Expansion in AFM Market Includes Appointment of New Executives April 23rd, 2016

GLOBALFOUNDRIES Adds Alain Mutricy as Head of Product Management Group March 3rd, 2016

George Clark Named Chief Financial Officer and Associate Laboratory Director for Business Services at Brookhaven Lab February 24th, 2016

NSS Pays Tribute to Late NSS Governor Dr. Marvin Minsky, A Pioneer in Artificial Intelligence February 11th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic